The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
Open accessAbstract
Interleukin (IL)-17A exists as a homodimer (A/A) or as a heterodimer (A/F) with IL-17F. IL-17A is expressed by a subset of T-cells, called Th17 cells, at inflammatory sites. Most cell types can respond to the local production of IL-17A because of the near ubiquitous expression of IL-17A receptors, IL-17RA and IL-17RC. IL-17A stimulates the release of cytokines and chemokines designed to recruit and activate both neutrophils and memory T-cells to the site of injury or inflammation and maintain a proinflammatory state. IL-17A-producing pathogenic T-cells contribute to the pathogenesis of autoimmune diseases, including psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. This study describes the generation and characterization of ixekizumab, a humanized IgG4 variant IL-17A-neutralizing antibody. Ixekizumab binds human and cynomolgus monkey IL-17A with high affinity and binds rabbit IL-17A weakly but does not bind to rodent IL-17A or other IL-17 family members. Ixekizumab effectively inhibits the interaction between IL-17A and its receptor in binding assays and potently blocks IL-17A-induced GRO or KC secretion in cell-based assays. In an in vivo mouse pharmcodynamic model, ixekizumab blocks human IL-17A-induced mouse KC secretion. These data provide a comprehensive preclinical characterization of ixekizumab, for which the efficacy and safety have been demonstrated in human clinical trials in psoriasis and psoriatic arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Th17 cells in immunity to Candida albicans
Hernández-Santos, N., & Gaffen, S. L. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.04.008 · Cited by 361
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
Cited by
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
Chiang, C.-C., Cheng, W.-J., Korinek, M., Lin, C.-Y., & Hwang, T.-L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02376 · Cited by 289
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Metadata
- Authors
- Liu, L., Kikly, K., Lu, J., Allan, B., Tang, Y., Tetreault, J., Chow, C.-K., Barmettler, B., Nelson, J., Bina, H., Huang, L., & Wroblewski, V.
- Venue
- Journal of Inflammation Research
- Publisher
- Informa UK Limited
- Published
- 2016-04
- Volume
- 9
- Pages
- 39
- ISSN
- 1178-7031 (ISSN-L)
- OpenAlex
- W2339525054
- Cited by
- 208
- References
- 6
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.